GENSCRIPT-BIOTECH
14.4.2021 07:32:13 CEST | Business Wire | Press release
GenScript Biotech (Netherlands) BV , a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
"With this collaboration, IES Diagnostics and GenScript will join forces to serve the local community with our expertise and resources. Since the outbreak of the worldwide pandemic in 2020, our company has been committed to supporting the global community in fighting COVID-19 with a comprehensive portfolio to support therapeutics and vaccine research and development, and diagnostic tool development including the novel cPass kit," said Aaron Qian, the President of European Division of GenScript.
Hubert Thomassen, CEO of IES Medical, said, "We are honored to be working with GenScript, proud to provide the unique and highly innovative cPass kit to our society that will contribute decisively to the knowledge of the immune status and level of protection of both those who have suffered a SARS-CoV-2 infection and those citizens who have been or will be vaccinated. The cPass kit is an essential tool in the development of any therapy aimed at combating this pandemic and in the development of an international immunity passport that allows our society to resume a normal social and economic life."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. The company’s operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript provides premium, convenient, and reliable products, and services for over 100,000 customers.
For more information visit http://www.genscript.com .
About IES Diagnostics
IES Diagnostics is the LifeScience division of IES Medical. IES Medical has its headquarters in Bilbao and offices in Madrid and Barcelona. The company directly serves clients all over the Iberian peninsula. IES Medical has a long-standing reputation for providing innovative products that contribute to improving the health of society in the areas of Emergency Medicine, Woundcare, Respiratory, and Diagnostics. The overall objective of IES Medical is to provide innovation for better care,
For more information visit https://www.iesmedical.es/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 16:30:00 CEST | Press release
Orchestration capabilities simplify workflows, while advanced agent connectivity and an enhanced context layer activate data and scale AI Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this visio
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 16:30:00 CEST | Press release
Companies team to deliver a unified, enterprise-scale agentic stack to help organizations with managing data sovereignty and optimizing AI costs Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexi
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 16:30:00 CEST | Press release
Partnership enables customers to accelerate AI agents from pilot to production with accuracy, performance, and control by combining Boomi's connectivity, agent runtime, and governance with Couchbase's operational data platform Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recolle
Lenovo Named a Leader and Star Performer in Mid-Market Digital Workplace Solutions Assessment by Everest Group13.5.2026 15:00:00 CEST | Press release
One of only two Star Performers, Lenovo was recognized for helping mid-market CIOs with cost reduction, faster onboarding, productivity gains Lenovo’s ability to help mid‑market organizations reduce IT support costs, accelerate time-to-value, and improve workforce productivity at scale has earned recognition as a Leader and Star Performer in Everest Group’s 2026 Digital Workplace Services PEAK Matrix® Assessment for Mid‑Market Enterprises. Lenovo’s Digital Workplace Solutions (DWS) enable customers to improve speed, cut costs, and elevate employee experiences, helping new employees reach productivity up to 50% faster, increasing employee satisfaction by 30%, lowering end-user support costs by up to 30%, and proactively resolving up to 40% of issues to minimize downtime and business disruption1. Lenovo delivers these results by uniquely integrating device, services, and intelligence into a single, scalable delivery model built for the mid‑market. Through lifecycle services delivered at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom